[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JO3787B1 - أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها - Google Patents

أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها

Info

Publication number
JO3787B1
JO3787B1 JOP/2013/0072A JOP20130072A JO3787B1 JO 3787 B1 JO3787 B1 JO 3787B1 JO P20130072 A JOP20130072 A JO P20130072A JO 3787 B1 JO3787 B1 JO 3787B1
Authority
JO
Jordan
Prior art keywords
antibodies
methods
cell proliferation
human anti
human
Prior art date
Application number
JOP/2013/0072A
Other languages
English (en)
Inventor
Wheeler John
Sweet Raymond
Chen John
Fransson Johan
Rycyzyn Michael
Scully Michael
Malia Thomas
Carlos Almagro Juan
Hamel Damon
Teplyakov Alexey
Fursov Natalie
Obmolova Galina
Ort Tatiana
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Application granted granted Critical
Publication of JO3787B1 publication Critical patent/JO3787B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

أجسام مضادة آدمية موجهة مناعيا ضد <span dir="LTR">CD27</span> الآدمي يمكن أن تمنع إرتباط <span dir="LTR">CD27</span> مع الليجاند الخاص به <span dir="LTR">CD70</span> ويعادل النشاط البيولوجي لـ <span dir="LTR">CD27</span> بما يتضمن على سبيل المثال وليس الحصر الإشارة بداخل الخلية لـ <span dir="LTR">CD27</span>، تكاثر الخلايا <span dir="LTR">T</span> وتنشيط تكاثر وتمايز الخلايا <span dir="LTR">B</span>، وتكوين الخلايا المكونة لخلايا البلازما وتخفيف استجابات الجسم المضاد، وتنشيط خلايا الأورام عن طريق <span dir="LTR">CD70</span>، وإنتاج مركبات وسيطة قابلة للذوبان من الخلايا <span dir="LTR">T </span> و<span dir="LTR">B</span>. تفيد تلك الأجسام المضادة في تشخيص أو علاج الحالات و الأمراض التي ترتبط بنشاط <span dir="LTR">CD27</span>.
JOP/2013/0072A 2012-03-15 2013-03-14 أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها JO3787B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261611332P 2012-03-15 2012-03-15

Publications (1)

Publication Number Publication Date
JO3787B1 true JO3787B1 (ar) 2021-01-31

Family

ID=49157853

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0072A JO3787B1 (ar) 2012-03-15 2013-03-14 أجسام مضادة بشرية ضد cd27 و طرق و استخداماتها

Country Status (28)

Country Link
US (6) US9102737B2 (ar)
EP (1) EP2825200A4 (ar)
JP (1) JP6487839B2 (ar)
KR (1) KR102153374B1 (ar)
CN (1) CN104284678B (ar)
AR (1) AR090356A1 (ar)
AU (1) AU2013232087B2 (ar)
BR (2) BR122020002414B1 (ar)
CA (1) CA2867299C (ar)
CL (1) CL2014002416A1 (ar)
CO (1) CO7071095A2 (ar)
CR (1) CR20140415A (ar)
EA (1) EA030828B1 (ar)
EC (1) ECSP14018641A (ar)
GT (1) GT201400193A (ar)
HK (1) HK1206251A1 (ar)
JO (1) JO3787B1 (ar)
MX (1) MX363946B (ar)
MY (1) MY175224A (ar)
NZ (1) NZ629697A (ar)
PE (1) PE20142242A1 (ar)
PH (2) PH12014502011A1 (ar)
SG (2) SG11201405437QA (ar)
TW (2) TW201730214A (ar)
UA (1) UA121844C2 (ar)
UY (1) UY34680A (ar)
WO (1) WO2013138586A1 (ar)
ZA (2) ZA201407440B (ar)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201690310A1 (ru) 2010-04-13 2016-12-30 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
PT2686347T (pt) 2011-03-16 2018-07-05 Argenx Bvba Anticorpos dirigidos contra cd70
WO2014140374A2 (en) * 2013-03-15 2014-09-18 Novo Nordisk A/S Monovalent cd27 antibodies
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
FR3025517B1 (fr) * 2014-09-10 2016-12-23 Repropharm Ligands potentialisants de la bioactivite des gonadotrophines
WO2017044752A1 (en) * 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
MA43055A (fr) * 2015-09-30 2018-08-08 Janssen Biotech Inc Anticorps agonistes se liant de manière spécifique au cd40 humain et procédés d'utilisation
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
JP6917368B2 (ja) * 2015-10-23 2021-08-11 アポジェニックス アーゲー 一本鎖ｃｄ２７受容体アゴニストタンパク質
WO2017117384A1 (en) 2015-12-31 2017-07-06 Development Center For Biotechnology Anti-vegfr antibody and uses thereof
EA201892362A1 (ru) 2016-04-18 2019-04-30 Селлдекс Терапьютикс, Инк. Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
CN116903741A (zh) 2016-06-20 2023-10-20 科马布有限公司 特异性结合于pd-l1的抗体或其抗原结合片段及其用途
JOP20190055A1 (ar) * 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
TW201813979A (zh) * 2016-09-29 2018-04-16 江蘇恆瑞醫藥股份有限公司 抗ｃｄ２７抗體、其抗原結合片段及其醫藥用途
US11242402B2 (en) 2016-12-23 2022-02-08 Macrogenics, Inc. ADAM9-binding molecules, and methods of use thereof
US11622977B2 (en) 2017-05-12 2023-04-11 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
US11166985B2 (en) 2017-05-12 2021-11-09 Crispr Therapeutics Ag Materials and methods for engineering cells and uses thereof in immuno-oncology
JP2020525470A (ja) * 2017-07-03 2020-08-27 ディヴェロップメント センター フォー バイオテクノロジー 抗ｖｅｇｆｒ抗体及びその使用
WO2019037131A1 (zh) * 2017-08-25 2019-02-28 深圳市博奥康生物科技有限公司 一种cd27真核表达载体的构建及其高表达细胞株的制备
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
WO2019156223A1 (ja) * 2018-02-09 2019-08-15 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
JP2021519088A (ja) * 2018-03-28 2021-08-10 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． 抗ｃｄ２７抗体、その抗原結合フラグメント及びその医学的使用
CN112292399A (zh) * 2018-04-04 2021-01-29 百时美施贵宝公司 抗cd27抗体及其用途
WO2019196117A1 (en) * 2018-04-13 2019-10-17 Dingfu Biotarget Co., Ltd. Anti-cd27 antibodies and use thereof
CN112292185A (zh) 2018-04-17 2021-01-29 塞德斯医疗公司 抗cd27和抗pd-l1抗体及双特异性构建体
MX2020012028A (es) 2018-05-11 2021-03-29 Crispr Therapeutics Ag Metodos y composiciones para tratar el cancer.
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
WO2020123444A1 (en) 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
US20220144961A1 (en) * 2019-03-11 2022-05-12 Xyence Therapeutics, Inc. Cd27-binding antibodies and uses thereof
SG11202112032WA (en) 2019-04-30 2021-11-29 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
CA3140914A1 (en) 2019-05-24 2020-12-03 Elixiron Immunotherapeutics (hong Kong) Limited Anti-csf1r antibodies, il10 fusion proteins, and uses thereof
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
CN112646029B (zh) * 2020-12-30 2022-07-29 深圳清华大学研究院 成熟脑源性神经营养因子的抗体及其应用和诊断试剂盒
AU2022246895A1 (en) 2021-03-31 2023-10-19 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
CN116120451A (zh) * 2021-06-17 2023-05-16 南京蓝盾生物科技有限公司 抗cd70内化的抗体、抗体偶联物及其应用
JP2024525475A (ja) 2021-06-29 2024-07-12 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションを促進するように操作された免疫細胞及びその使用
WO2023178192A1 (en) 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
CN118667002A (zh) * 2023-03-16 2024-09-20 上海赛金生物医药有限公司 抗cd27单克隆抗体及其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218525B1 (en) 1988-02-25 2001-04-17 The General Hospital Corporation Nucleic acid encoding CD28
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1992019759A1 (en) 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5573924A (en) 1992-09-08 1996-11-12 Immunex Corporation CD27 ligand
US7148061B2 (en) 2000-02-11 2006-12-12 The United States Of America As Represented By The Department Of Health And Human Services Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
US6982361B1 (en) 2000-02-25 2006-01-03 The Regents Of The University Of California Method of screening a compound for anxiolytic activity in an Apolipoprotein e knockout animal
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
WO2003025019A1 (en) 2001-09-20 2003-03-27 Alexion Pharmaceuticals, Inc. Anti-pdgf antibodies and methods for producing engineered antibodies
AU2003210266A1 (en) 2002-02-14 2003-09-04 Bioinvent International Ab Treatment, diagnosis and imaging of disease
WO2004074320A2 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic targets in cancer
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
US20110129412A1 (en) 2005-06-02 2011-06-02 Astrazeneca Ab Antibodies Directed to CD20 and Uses Thereof
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
EP2090320A1 (en) * 2008-02-15 2009-08-19 Helmholtz-Zentrum für Infektionsforschung GmbH Ligands of the Natural Killer (NK) cell surface marker CD27 and therapeutic uses thereof
AU2009267294B2 (en) * 2008-06-30 2014-06-26 Kyowa Kirin Co., Ltd. Anti-CD27 antibody
CN102918059A (zh) * 2009-12-29 2013-02-06 协和发酵麒麟株式会社 抗cd27抗体
EA201690310A1 (ru) * 2010-04-13 2016-12-30 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
WO2012004367A1 (en) * 2010-07-09 2012-01-12 N.V. Organon Agonistic antibody to cd27

Also Published As

Publication number Publication date
US20170320957A1 (en) 2017-11-09
CO7071095A2 (es) 2014-09-30
CA2867299C (en) 2019-08-27
UA121844C2 (uk) 2020-08-10
PH12017501908A1 (en) 2018-10-01
HK1206251A1 (en) 2016-01-08
US20240141055A1 (en) 2024-05-02
CL2014002416A1 (es) 2015-01-16
US20130243795A1 (en) 2013-09-19
US11732050B2 (en) 2023-08-22
KR20140133940A (ko) 2014-11-20
EA030828B1 (ru) 2018-10-31
MY175224A (en) 2020-06-16
PE20142242A1 (es) 2015-01-08
CN104284678A (zh) 2015-01-14
ZA201500887B (en) 2016-01-27
PH12014502011B1 (en) 2014-11-24
BR112014022812A2 (pt) 2017-07-18
AU2013232087B2 (en) 2018-02-08
ZA201407440B (en) 2016-07-27
US20200277393A1 (en) 2020-09-03
ECSP14018641A (es) 2018-10-31
AU2013232087A1 (en) 2014-09-25
NZ629697A (en) 2017-01-27
CN104284678B (zh) 2018-04-24
MX2014011100A (es) 2014-12-05
KR102153374B1 (ko) 2020-09-10
CA2867299A1 (en) 2013-09-19
MX363946B (es) 2019-04-09
WO2013138586A1 (en) 2013-09-19
US20150299330A1 (en) 2015-10-22
US10301392B2 (en) 2019-05-28
US9102737B2 (en) 2015-08-11
AR090356A1 (es) 2014-11-05
UY34680A (es) 2013-09-30
JP6487839B2 (ja) 2019-03-20
JP2015511965A (ja) 2015-04-23
PH12017501908B1 (en) 2018-10-01
EP2825200A1 (en) 2015-01-21
TW201345922A (zh) 2013-11-16
US10689453B2 (en) 2020-06-23
SG11201405437QA (en) 2014-10-30
PH12014502011A1 (en) 2014-11-24
TW201730214A (zh) 2017-09-01
BR122020002414B1 (pt) 2022-03-03
SG10201710574UA (en) 2018-02-27
CR20140415A (es) 2014-11-18
US9683046B2 (en) 2017-06-20
US20190248910A1 (en) 2019-08-15
GT201400193A (es) 2017-06-14
EA201491700A1 (ru) 2015-02-27
EP2825200A4 (en) 2015-08-26
TWI576354B (zh) 2017-04-01

Similar Documents

Publication Publication Date Title
PH12017501908A1 (en) Human anti-cd27 antibodies, methods and uses
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
EA033400B1 (ru) Антитело против cd3 и его применение
WO2011143318A3 (en) Anti-fgfr2 antibodies
PH12016501728A1 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
MY171234A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
MX349057B (es) Agente terapeutico que induce citotoxicidad.
JOP20110402B1 (ar) الأجسام المضادة ل cd38
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
EP4309671A3 (en) Methods for increasing efficacy of folr1 cancer therapy
EA201590870A1 (ru) АМИНОЗАМЕЩЕННЫЕ ИМИДАЗО[1,2-a]ПИРИДИНКАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ
MX2019006379A (es) Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer.
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
DK201300530A (en) Vaccine relating to Pancreas disease in fish
EA201500232A1 (ru) Три(гетеро)арилпиразолы и их применение
WO2016179529A3 (en) Radiotherapeutic and companion imaging agents to target mc1r
WO2012102753A3 (en) Metalloproteinase oligopeptides and their therapeutic use
陈若琨 et al. RRP22, a new neural tumor suppressor for gliomas
WO2014172653A3 (en) Anti-notch1 antibodies
EA201992798A3 (ru) Антитела против pd1 и их применение в качестве терапевтических и диагностических средств
TN2013000265A1 (en) Anti-cd38 antibodies
WO2014009245A3 (en) Novel drug target indentification methods
MX355467B (es) Anticuerpos terapeuticos.